Skip to content

Evaluation of a Decision Aid for Adult Cystic Fibrosis Patients Considering Bilateral Lung Transplantation

Evaluation of a Decision Aid for Adult Cystic Fibrosis Patients Considering Bilateral Lung Transplantation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00345449
Enrollment
200
Registered
2006-06-28
Start date
2006-09-30
Completion date
2008-09-30
Last updated
2009-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

cystic fibrosis,, lung disease,, lung transplantation,, decision aid

Brief summary

In 2006, the International Patient Decision Aids Collaboration (IPDAS) reached agreement on criteria for evaluation. Accordingly, the primary outcome is 'decision quality' 3 weeks after using the decision aid. Decision quality is defined as the extent to which a patient decision aid improves the match between the chosen option and the features that matter most to the informed patient. Measures include: a) patients' knowledge of essential facts \[options, benefits, harms, and outcome probabilities\]; and b. the congruence between the option chosen and patients' informed values regarding benefits and risks. In the past twenty years lung transplantation has become the most widely accepted option of treating cystic fibrosis patients with severe lung disease. Lung transplantation can be a good experience for many patients, improving their quality of life and their survival. However there are potential risks of lung transplantation including infection, organ rejection and early death. Cystic fibrosis patients are often faced with making a choice of whether to be referred for lung transplantation when they are very sick and there is the immediate need to survive. Our group has developed a tool called a decision aid which we hope will assist the patient and family in making this choice. The decision aid guides the patient through a series of steps where they weigh the benefits and risks of being referred for lung transplantation and the benefits and risks of receiving 'usual care' without the option of referral.

Detailed description

Patients randomized to either arm of the study will be required to undergo a lung transplantation education and counselling session with their CF physician prior to randomization. Subsequent to this session patients will be randomly allocated to receive: 1) usual care plus the patient decision aid or 2) usual care. For purposes of this study, usual care will include a booklet entitled, Cystic fibrosis and lung transplantation written by the Canadian Cystic Fibrosis Foundation plus any other written or educational material that the local CF centre normally provides.

Interventions

BEHAVIORALDecision Aid

Sponsors

Ottawa Hospital Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* FEV less than or equal to 40% predicted

Exclusion criteria

* Patients unable to provide informed consent * Patients on a lung transplant waiting list * Patients who are lung transplant recipients * Patients deemed too sick for transplant * Only one sibling per family to minimize contamination

Design outcomes

Primary

MeasureTime frame
Knowledge, realistic expectations and decisional conflict 3 weeks after using the decision aid.

Secondary

MeasureTime frame
Durability of the decision one year after the patient decision aid.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026